GENMAB A/S (GMAB)
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (81%) **Content type:** Clinical